Infectious Disease Control

Fosun International Receives "ESG Leading Enterprise Award" and "ESG Leading Social Initiative Award" from Bloomberg Businessweek/Chinese Edition

HONG KONG, Dec. 14, 2022 /PRNewswire/ -- On 12 December 2022, the results of the fourth ESG Leading Enterprise Awards 2022, which was organized by the Chinese Edition of Bloomberg Businessweek in partnership with Deloitte, one of the world's largest accounting firms, and with the support from Inv...

2022-12-14 11:09 4510

CGTN: The Chinese are sharing their COVID experiences as policy optimized

BEIJING, Dec. 13, 2022 /PRNewswire/ -- Vincent Zhong is a Chinese digital gadget YouTuber with more than 372,000 followers. Aside from smartphones, earbuds and laptops, Zhong recently unboxed a special object: COVID-19. "I'm screwed," Zhong said in a video showing a positive COVID test result on ...

2022-12-13 12:49 3189

Epidemic: Modified approach ensures maximum benefit

BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from chinadaily.com.cn: After three years of battling COVID-19, experts said China is seeing the light at the end of the tunnel as it continues to optimize measures against the epidemic.

2022-12-13 11:42 2274

CGTN: Infrastructure, vaccines and space: China-Arab sci-tech cooperation

BEIJING, Dec. 12, 2022 /PRNewswire/ -- Under the Belt and Road Initiative (BRI), China-Arab cooperation in the fields of infrastructure, space and health has been continuously developed in a sustainable manner. China has vowed to ...

2022-12-12 15:39 3869

China further optimizes COVID-19 response with new measures

BEIJING, Dec. 12, 2022 /PRNewswire/ -- A report from People's Daily: Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by the country on further optimizing the COVID-19 response, so as to contain the epidemi...

2022-12-12 11:38 2581

China recalibrates its COVID-19 response strategy

BEIJING, Dec. 12, 2022 /PRNewswire/ -- After months of lining up every two to three days to take a nucleic acid test at temporary testing stations dotting the urban landscape, many Chinese residents were pleasantly surprised to learn onDecember 7 that they would no longer be required to take the ...

2022-12-12 10:22 2428

Asia embraces the dawn

HONG KONG, Dec. 10, 2022 /PRNewswire/ -- A photo exhibition that captures the changes in Asian people's daily lives under the COVID-19 pandemic and encourages people to move forward opened inHong Kong on Friday. Co-organized by China Daily and the Asia News Network, the Changing Asia – New Norma...

2022-12-10 00:31 10072

Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...

2022-12-05 20:00 2125

Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents

SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...

2022-11-28 22:59 5057

Australian Scientists Honoured with the Grand Hamdan Award

DUBAI, UAE, Nov. 25, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place  on 23rd of November the Museum of the Future. The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of SheikhRas...

2022-11-25 10:39 4059

Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA

--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...

2022-11-23 19:43 4862

Immorna Receives IND Clearance to Conduct a Phase 1/2 Study of JCXH-221, a Broadly Protective mRNA-Based COVID-19 Vaccine

MORRISVILLE, N.C., Nov. 21, 2022 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) a...

2022-11-21 20:00 2481

APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival

GENEVA, Nov. 21, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease ar...

2022-11-21 18:56 5248

Manulife Hong Kong expands partnership with Christian Family Service Centre to support long COVID recovery in underserved communities

New program to provide comprehensive healthcare services to empower sustained health and better wellbeing HONG KONG, Nov. 17, 2022 /PRNewswire/ -- Manulife Hong Kong today announced the launch of "Manulife Health Voucher Program – COVID Recovery" (hereafter referred to as the "Program") in partn...

2022-11-17 14:22 3323

BioVaxys Sarbecovirus Vaccine Interim Data Excellent Emerging Safety & Tolerability Profile with BVX-1021

VANCOUVER, BC, Nov. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that interim results from its ongoing preclinical of BVX-1021, the Company's vaccine for SARS-CoV-1 ("SARS1") which is being evaluated in a...

2022-11-16 21:00 5617

Tianlong Showcases Innovative Smart PCR Lab Solution at Medica 2022

XI'AN, CHINA, Nov. 15, 2022 /PRNewswire/ -- From November 14 to 17, Tianlong's newly-launched smart PCR lab solution will showcase at Medica 2022 in Dusseldorf, Germany. The innovative smart PCR lab solution from Tianlong can maximize resources by making the best use of people, space, and equipmen...

2022-11-15 21:19 3820

WuXi Vaccines Establishes New Vaccines CDMO Facility in China

SUZHOU, China, Nov. 15, 2022 /PRNewswire/ -- WuXi Vaccines, a leading global Contract Development and Manufacturing Organization (CDMO), announced that it has entered into an agreement with Harbour BioMed under which Harbour BioMed's manufacturing facility in Suzhou will be transferred to WuXi Va...

2022-11-15 12:45 3017

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

* The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary * Novavax' prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains * The trial showed no benefit for a bivalent vaccin...

2022-11-08 21:00 5241

Traditional Chinese Medicine Lianhua Qingwen Attracted Eyes in the Annual National Conference of Pharmaceutical Society of Nigeria

SHIJIAZHUANG, China, Nov. 8, 2022 /PRNewswire/ -- Recently, the 95th National Annual Conference of the Pharmaceutical Society ofNigeria was held in Jos, capital of Plateau State. The theme of the Conference in this year was "Medicine Security in an Unstable Economy", and more than 3,000 doctors a...

2022-11-08 20:25 2600

Lunit Highlights the Effectiveness of AI in Acceleration of Immunotherapy Research--Findings to be Presented at SITC 2022

* Lunit to present three abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping. * Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO in accelerating immunotherapy clinical trials and drug development. SEOUL, South Korea, Nov. 7, ...

2022-11-07 21:00 2794
1 ... 10111213141516 ... 34